PARTI Overview We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Currently available therapies for these diseases are limited, with many diseases having no approved therapies or treatments. Our goal is to develop disease-modifying treatments for patients with these degenerative disorders. Our lead product ...
Q2 FY2026 — expected 2026-09-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-26 | 2025-12-31 | 0001104659-26-034880 | EDGAR | 88K words |
| 2025-03-20 | 2024-12-31 | 0001558370-25-003341 | EDGAR | — |
| 2024-03-26 | 2023-12-31 | 0001558370-24-003949 | EDGAR | — |
| 2023-03-23 | 2022-12-31 | 0001558370-23-004401 | EDGAR | — |
| 2022-03-30 | 2021-12-31 | 0001558370-22-004672 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001104659-25-107402 | EDGAR | 24K words |
| 2025-08-07 | 2025-06-30 | 0001558370-25-010771 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0001558370-25-006612 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001558370-24-015436 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001558370-24-011464 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001558370-24-006911 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0001558370-23-017321 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001558370-23-013741 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001558370-23-008117 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001558370-22-017604 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001558370-22-012749 | EDGAR | — |
| 2022-05-11 | 2022-03-31 | 0001558370-22-008230 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-26 | 0001104659-26-034876 | EDGAR | 3K words |
| 2026-03-02 | 0001104659-26-021904 | EDGAR | — |
| 2026-01-27 | 0001104659-26-006813 | EDGAR | — |
| 2025-12-18 | 0001104659-25-122555 | EDGAR | — |
| 2025-11-06 | 0001104659-25-107390 | EDGAR | — |
| 2025-09-15 | 0001104659-25-089737 | EDGAR | — |
| 2025-08-28 | 0001104659-25-084845 | EDGAR | — |
| 2025-08-26 | 0001104659-25-083059 | EDGAR | — |
| 2025-08-07 | 0001104659-25-075268 | EDGAR | — |
| 2025-06-20 | 0001104659-25-061142 | EDGAR | — |
103 total filings indexed. 76 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001455365 |
| Ticker | CGTX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.cogrx.com |
| Listed | 2021-10-08 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report